Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical Co's quarterly finished goods
increased
from Sep. 2025 (円25,423 Mil) to Dec. 2025 (円26,435 Mil) but then
declined
from Dec. 2025 (円26,435 Mil) to Mar. 2026 (円23,873 Mil).
Kyorin Pharmaceutical Co's annual finished goods
increased
from Mar. 2024 (円18,795 Mil) to Mar. 2025 (円22,558 Mil) and
increased
from Mar. 2025 (円22,558 Mil) to Mar. 2026 (円23,873 Mil).
Kyorin Pharmaceutical Co Inventories, Finished Goods Historical Data
* Premium members only.
The historical data trend for Kyorin Pharmaceutical Co's Inventories, Finished Goods can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co Inventories, Finished Goods Chart
What does a Inventories, Finished Goods of 円23,873 Mil mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Inventories, Finished Goods of 円23,873 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Kyorin Pharmaceutical Co and its competitors.
Is Kyorin Pharmaceutical Co's Inventories, Finished Goods too high?
Kyorin Pharmaceutical Co's current Inventories, Finished Goods is 円23,873 Mil. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Inventories, Finished Goods compare to ZTS and UTHR?
Kyorin Pharmaceutical Co's Inventories, Finished Goods of 円23,873 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Kyorin Pharmaceutical Co and its competitors. Kyorin Pharmaceutical Co's current Inventories, Finished Goods is 円23,873 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,582.64, compared to a current price of 円1,177.00 — trading 25.6% below its estimated fair value. The current Inventories, Finished Goods is 円23,873 Mil. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Inventories, Finished Goods is 円23,873 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,177.00 is trading 25.6% below its estimated GF Value™ of 円1,582.64.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
Inventories, Finished Goods: 円23,873 Mil
GF Value™: 円1,582.64 vs. price of 円1,177.00 (25.6% below fair value)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for TSE:4569
Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
